USRE41390E1 - Trace elements - Google Patents
Trace elements Download PDFInfo
- Publication number
- USRE41390E1 USRE41390E1 US12/353,504 US35350409A USRE41390E US RE41390 E1 USRE41390 E1 US RE41390E1 US 35350409 A US35350409 A US 35350409A US RE41390 E USRE41390 E US RE41390E
- Authority
- US
- United States
- Prior art keywords
- edta
- solution
- trace element
- complex
- element solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/40—Mineral licks, e.g. salt blocks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the invention discloses a method of preparing a trace element solution, which includes the steps of providing at least one EDTA-complex; of providing a sodium selenite solution; and of combining the EDTA-complex(es) and the sodium selenite solution.
- the invention further discloses at least one EDTA complex prepared by using disodium EDTA or EDTA acid; selenium; and any other suitable mineral.
- the present invention relates to trace elements.
- U.S. Pat. No. 4,335,116 (Howard) discloses mineral-containing therapeutic compositions containing EDTA complexes of trace elements.
- U.S. Pat. No. 4,335,116 utilises tetra-sodium EDTA, a selenium glycine complex, and metal chlorides for the preparation of the EDTA complexes.
- the chloride ions cause contamination and each complex solution is to be made individually.
- overnight time is required for complexing and heating up afterward to speed up the process requires extra apparatus.
- mixtures are required, the individual solutions are to be blocked.
- various concentrations as well as compositions are to be made, it can only be done in a cumbersome way, requiring extra apparatus.
- a further problem may arise when mixtures of high concentration are needed. In certain cases it would be impossible to deliver them, because mixing is always accompanied by dilution.
- EDTA refers to ethylene diaminotetraacetic acid (C 10 ,H 16 O 8 N 2 or (HO 2 CH 2 C) 2 NCH 2 CH 2 N-(CH 2 CO 2 H) 2 ).
- a method of preparing a trace element solution includes the steps
- these EDTA-complexes may be prepared in a single continuous process.
- the EDTA-complex(es) may be prepared by using disodium EDTA or EDTA acid.
- the EDTA-complex(es) may be prepared by using at least one selected from the group consisting of metal oxides, metal hydroxides and metal carbonates.
- the EDTA-complex(es) may include at least one of the metal compounds selected from the group consisting of copper, manganese, zinc, molybdenum and chromium.
- a trace element solution includes
- the solution may be an injectable solution.
- the solution may be a drenchable solution.
- a stock lick includes
- a method of providing trace elements to animals includes the steps of preparing a trace element solution set out herein and of providing the solution in a suitable quantity to an animal.
- EDTA is suspended in a quantity of distilled water at 50° C. and is stirred continuously. In small proportions firstly sodium hydroxide (NaOH) and then zinc oxide (ZnO) are added in sequence. The pH of the clear solution obtained is measured and brought to 7, if necessary, by either the addition of NaOH (if acid) or EDTA (if alkaline). More distilled water is added to bring the zinc concentration to a predetermined level, and the solution is subsequently filtered.
- NaOH sodium hydroxide
- ZnO zinc oxide
- the zinc concentration in the solution will be 20 mg/ml.
- Manganese carbonate (MnCO 3 .xH 2 O) is used in place of zinc oxide.
- the manganese concentration will be 20 mg/ml.
- the copper concentration in the solution will be 10 mg/ml.
- Chromium tri-chloride hexahydrate (CrCl 3 .6H 2 O) is used in the place of zinc oxide.
- the chromium concentration in the solution will be 5 mg/ml.
- the selenium concentration in the solution will be 5 mg/ml.
- the method is a combination of the above methods under Examples 1, 2, 3, 4 and 5 and takes place as follows:
- the zinc concentration will be 20 mg/ml, the manganese concentration 20 mg/ml, copper concentration 10 mg/ml, the chromium concentration 5 mg/ml and the selenium concentration 5 mg/ml.
- Molybdenum tri-oxide (MoO 3 ) is suspended at room temperature in a quantity of water and stirred continuously. In portions in sequence firstly sodium hydroxide (NaOH) and then EDTA are added. The pH of the clear solution obtained is measured and it is brought to 7 if required, by adding either NaOH (if acid) or EDTA (if alkaline). More distilled water is added to bring the molybdenum concentration to a pre-determined value. The pH is changed to 6 by the addition of concentrated HCl. Filtration takes place.
- NaOH sodium hydroxide
- EDTA if alkaline
- the molybdenum concentration will be 40 mg/ml.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Compounds Of Iron (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
-
- (a) of providing at least one EDTA-complex;
- (b) of providing a sodium selenite solution; and
- (c) of combining the EDTA-complex(es) and the sodium selenite solution.
-
- (a) at least one EDTA complex prepared by using disodium EDTA or EDTA acid;
- (b) selenium; and
- (c) any other suitable mineral.
-
- (a) at least one EDTA complex prepared by using disodium EDTA or EDTA acid;
- (b) selenium; and
- (c) any other suitable mineral.
-
- 1. The zinc preparation as per Example 1 is prepared.
- 2. To this added (in the same container) the chemicals as used for Example 2 for the preparation of the manganese compound.
- 3. Then the chemicals used as under Example 3 for the preparation of the copper compound are added.
- 4. At this stage the pH is brought to 7 as described under Example 1 above.
- 5. Subsequently the chemicals used as under Example 4 for the preparation of the chromium compound are added.
- 6. Lastly the chemicals used as under Example 5 are added.
- 7. Finally the total volume is adapted by the addition of distilled water.
- 8. Filtration takes place.
-
- 1. The di-sodium salt of EDTA in place of EDTA acid.
- 2. Basic zinc carbonate (2ZnCO3.3Zn(OH)2) or zinc hydroxide (Zn(OH)2) in place of zinc oxide.
- 3. Manganese hydroxide (Mn(OH)2) in place of manganese carbonate.
- 4. Cupric hydroxide (Cu(OH)2) or cupric oxide (CuO) in place of basic copper carbonate.
- 5. Anhydrous chromium tri-chloride (CrCl3) in place of chromium tri-chloride hexahydrate.
- 6. Sodium molybdate (Na2MoO4) in place of molybdenum tri-oxide.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/353,504 USRE41390E1 (en) | 2000-08-28 | 2009-01-14 | Trace elements |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2000/4456 | 2000-08-28 | ||
| ZA200004456 | 2000-08-28 | ||
| US09/935,550 US6638539B2 (en) | 2000-08-28 | 2001-08-24 | Trace elements |
| US12/353,504 USRE41390E1 (en) | 2000-08-28 | 2009-01-14 | Trace elements |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/935,550 Reissue US6638539B2 (en) | 2000-08-28 | 2001-08-24 | Trace elements |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE41390E1 true USRE41390E1 (en) | 2010-06-22 |
Family
ID=25588884
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/935,550 Ceased US6638539B2 (en) | 2000-08-28 | 2001-08-24 | Trace elements |
| US10/693,955 Expired - Fee Related US8231910B2 (en) | 2000-08-28 | 2003-10-28 | Trace elements |
| US12/353,504 Expired - Lifetime USRE41390E1 (en) | 2000-08-28 | 2009-01-14 | Trace elements |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/935,550 Ceased US6638539B2 (en) | 2000-08-28 | 2001-08-24 | Trace elements |
| US10/693,955 Expired - Fee Related US8231910B2 (en) | 2000-08-28 | 2003-10-28 | Trace elements |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6638539B2 (en) |
| EP (1) | EP1339416B1 (en) |
| AU (2) | AU7999401A (en) |
| BR (1) | BR0113668A8 (en) |
| CA (2) | CA2420766C (en) |
| DK (1) | DK1339416T3 (en) |
| ES (1) | ES2394080T3 (en) |
| MX (1) | MXPA03001836A (en) |
| NZ (1) | NZ524848A (en) |
| WO (1) | WO2002017933A1 (en) |
| ZA (1) | ZA200106875B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7999401A (en) * | 2000-08-28 | 2002-03-13 | Gavin Derek Mitchell | Trace elements |
| AU2002351537A1 (en) * | 2002-10-31 | 2004-06-18 | Piotr Zajac | Feed additive and process for manufacturing thereof |
| US7285292B2 (en) * | 2004-04-29 | 2007-10-23 | Warburton Technology Limited | Trace elements |
| ES2908870T3 (en) | 2004-05-03 | 2022-05-04 | Warburton Technology Ltd | trace elements |
| EP2301557A1 (en) * | 2004-09-09 | 2011-03-30 | Warburton Technology Limited | Trace elements |
| US9750764B2 (en) | 2008-12-09 | 2017-09-05 | Warburton Technology Limited | Trace elements |
| US20110076341A1 (en) * | 2009-09-25 | 2011-03-31 | William Alfred Smith | Trace elements |
| DK3915569T3 (en) | 2012-05-14 | 2023-08-21 | Warburton Technology Ltd | METHOD OF PREPARING A TRACE ELEMENT SOLUTION |
| CN108135931A (en) | 2015-10-09 | 2018-06-08 | 沃伯顿科技有限公司 | trace element solution |
| GB201607814D0 (en) | 2016-05-04 | 2016-06-15 | 5D Health Prot Group Ltd | Anti-microbial compositions |
| EP3740463B1 (en) | 2018-01-19 | 2025-05-21 | Koch Agronomic Services, LLC | Multi-source micronutrient composition and methods of treating soil with the same |
| PT3996720T (en) * | 2019-07-12 | 2025-05-07 | Chemvet Australia Pty Ltd | Injectable nutritional supplement |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4335116A (en) * | 1980-10-07 | 1982-06-15 | University Patents, Inc. | Mineral-containing therapeutic compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU187467B (en) | 1981-11-02 | 1986-01-28 | Vetoemagtermeltetoe Es Ertekesitoe Vallalat,Hu | Method for producing preparation suitable for preventing health deterioration of alimentary origin promoting the utilization of fodder of animals |
| HUT58194A (en) * | 1990-08-29 | 1992-02-28 | Nyirseg Konzervipari Vallalat | Method for producing foodstuff-preparations suitable for introducing biologically important micro- and macro-elements |
| DE19617185A1 (en) * | 1996-04-29 | 1997-10-30 | Muehle Ebert Dielheim Gmbh | New horse feedstuffs containing bioactive trace metals |
| AU7999401A (en) * | 2000-08-28 | 2002-03-13 | Gavin Derek Mitchell | Trace elements |
| US20030021836A1 (en) * | 2001-04-20 | 2003-01-30 | Spencer Feldman | Magnesium di-potassium EDTA complex and method of administration |
| US7670688B2 (en) * | 2001-06-25 | 2010-03-02 | Applied Materials, Inc. | Erosion-resistant components for plasma process chambers |
| US7285292B2 (en) * | 2004-04-29 | 2007-10-23 | Warburton Technology Limited | Trace elements |
-
2001
- 2001-08-17 AU AU7999401A patent/AU7999401A/en active Pending
- 2001-08-17 BR BRPI0113668A patent/BR0113668A8/en not_active IP Right Cessation
- 2001-08-17 EP EP01958270A patent/EP1339416B1/en not_active Expired - Lifetime
- 2001-08-17 AU AU2001279994A patent/AU2001279994B2/en not_active Expired
- 2001-08-17 CA CA002420766A patent/CA2420766C/en not_active Expired - Lifetime
- 2001-08-17 MX MXPA03001836A patent/MXPA03001836A/en active IP Right Grant
- 2001-08-17 NZ NZ524848A patent/NZ524848A/en not_active IP Right Cessation
- 2001-08-17 ES ES01958270T patent/ES2394080T3/en not_active Expired - Lifetime
- 2001-08-17 CA CA2589059A patent/CA2589059C/en not_active Expired - Lifetime
- 2001-08-17 WO PCT/IB2001/001486 patent/WO2002017933A1/en not_active Ceased
- 2001-08-17 DK DK01958270.9T patent/DK1339416T3/en active
- 2001-08-21 ZA ZA200106875A patent/ZA200106875B/en unknown
- 2001-08-24 US US09/935,550 patent/US6638539B2/en not_active Ceased
-
2003
- 2003-10-28 US US10/693,955 patent/US8231910B2/en not_active Expired - Fee Related
-
2009
- 2009-01-14 US US12/353,504 patent/USRE41390E1/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4335116A (en) * | 1980-10-07 | 1982-06-15 | University Patents, Inc. | Mineral-containing therapeutic compositions |
Non-Patent Citations (2)
| Title |
|---|
| Package label from product sold from 1999-2001, identified as Multimin(TM). |
| Package label from product sold from 1999-2001, identified as Multimin™. |
Also Published As
| Publication number | Publication date |
|---|---|
| US6638539B2 (en) | 2003-10-28 |
| US20020068079A1 (en) | 2002-06-06 |
| AU7999401A (en) | 2002-03-13 |
| BRPI0113668B1 (en) | 2015-08-11 |
| CA2589059A1 (en) | 2002-03-07 |
| CA2420766A1 (en) | 2002-03-07 |
| EP1339416A1 (en) | 2003-09-03 |
| ES2394080T3 (en) | 2013-01-17 |
| WO2002017933A1 (en) | 2002-03-07 |
| EP1339416B1 (en) | 2012-11-07 |
| NZ524848A (en) | 2004-07-30 |
| BR0113668A (en) | 2003-06-03 |
| US8231910B2 (en) | 2012-07-31 |
| CA2589059C (en) | 2011-10-04 |
| EP1339416A4 (en) | 2004-02-04 |
| CA2420766C (en) | 2007-12-11 |
| AU2001279994B2 (en) | 2004-09-02 |
| BR0113668A8 (en) | 2018-03-06 |
| ZA200106875B (en) | 2001-09-05 |
| US20040235945A1 (en) | 2004-11-25 |
| MXPA03001836A (en) | 2004-03-26 |
| DK1339416T3 (en) | 2013-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10729772B2 (en) | Trace elements | |
| US12168025B2 (en) | Trace elements | |
| US8231910B2 (en) | Trace elements | |
| US20230114516A1 (en) | Trace element solution | |
| AU2001279994A1 (en) | Trace elements | |
| CA2556813C (en) | Trace elements | |
| US20110076341A1 (en) | Trace elements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |
|
| AS | Assignment |
Owner name: U.S. BANK NATIONAL ASSOCIATION, NORTH CAROLINA Free format text: SECURITY INTEREST;ASSIGNOR:WARBURTON TECHNOLOGY LIMITED;REEL/FRAME:051363/0001 Effective date: 20191206 |
|
| AS | Assignment |
Owner name: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, NORTH CAROLINA Free format text: ASSIGNMENT AND ASSUMPTION AGREEMENT;ASSIGNOR:U.S. BANK NATIONAL ASSOCIATION;REEL/FRAME:063115/0486 Effective date: 20220128 |
|
| AS | Assignment |
Owner name: AXIOTA U.S., INC. (F/K/A MS BIOTECH, INC.), COLORADO Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (AS SUCCESSOR IN INTEREST TO U.S. BANK NATIONAL ASSOCIATION), AS ADMINISTRATIVE AGENT;REEL/FRAME:073791/0089 Effective date: 20260213 Owner name: WARBURTON TECHNOLOGY LIMITED, IRELAND Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (AS SUCCESSOR IN INTEREST TO U.S. BANK NATIONAL ASSOCIATION), AS ADMINISTRATIVE AGENT;REEL/FRAME:073791/0089 Effective date: 20260213 |
|
| AS | Assignment |
Owner name: ALTER DOMUS (US), LLC, AS ADMINISTRATIVE AGENT, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:WARBURTON TECHNOLOGY LIMITED;REEL/FRAME:074840/0269 Effective date: 20260603 |